Buffett smells opportunity in Tylenol mis-manufacturing

Apparently GMP violations have an odor detectable by high-stakes investors as well as the FDA. Warren Buffet is taking his eye off of Genzyme CEO Henri Termeer for the moment and casting it toward Johnson & Johnson and Bill Weldon.

Berkshire Hathaway has upped its stake in J&J by about 18 million shares. The move fits the Buffet "investment thesis," reports TheStreet: The stock price is depressed, off about $20 per share, trading at about $59 on Tuesday.

A Morningstar analyst attributes the weakness to the recent black eye the company is suffering from the Tylenol recalls. Still, the OTC business is just one percent of J&J sales. The impact is expected be short term and likely to be corrected within two years, according to the article. Perhaps not all analysts are aware of the pace in a GMP-violation comeback.

Termeer of Genzyme just recently made a peace of sorts with Buffett, but only after some board changes appeased him.

- see the article

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.